INOVOTION

📍 La Tronche, France🗓 Founded 2014👥 18 employees💰 Last funded Jun 2018
INOVOTION is a biotech company which offers you a unique in vivo technology dedicated to anti-cancer treatment evaluations and early toxicity studies. Our Fast, Sensitive, Reliable and Affordable assay will save you time and money, to give you a clear competitive advantage. This breaking-thought technology, based on chick embryo, provides early analysis of your treatments before the classical preclinical stages. By eliminating low-value molecules early, INOVOTION accelerates your drug discovery process, increases your R&D productivity and reduces its costs. It’s rapid Go/No Go decision with multi-cancer screening capacities. This next generation of in vivo efficacy and toxicity tests covers fours main aspects: - EFFICACY assays for your anti-cancer treatments - EARLY TOXICITY assays for your drug candidates - TARGET VALIDATION in oncology - MULTI-CANCER SCREENING to (re)positioning your treatment We help chemists and biologists from companies and universities to validate a target and develop treatments by getting them through in vivo evaluation, while staying within their budget. These accessible efficacy and toxicity assays open really new perspectives of screening for wide variety of project researches with a rapid Go/No Go decisions. You want focus your R&D on your high-value molecules, contact us!
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2014
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in INOVOTION?
INOVOTION has 1 investors on record on gritt.io, 1 mid-stage.
When did INOVOTION last raise funding?
The most recent investment in INOVOTION recorded on gritt.io was in June 2018.
When was INOVOTION founded?
INOVOTION was founded in 2014.
What industry is INOVOTION in?
INOVOTION operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is INOVOTION based?
INOVOTION is headquartered in La Tronche, France.